New Evidence Supports Efficacy And Value Of Smith & Nephew NPWT Products

Main Category: Dermatology
Also Included In: Medical Devices / Diagnostics;  Conferences
Article Date: 25 Apr 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

Smith & Nephew Inc's (LSE: SN; NYSE: SNN) Advanced Wound Management division announced that nine clinical posters featuring its Negative Pressure Wound Therapy (NPWT) products will be presented at next week's Symposium on Advanced Wound Care (SAWC) and Wound Healing Society Meeting. The poster session is open from 7:30 to 9:00am on Monday, April 27, and will include a total of 15 additional posters on studies conducted with Smith & Nephew's ACTICOAT(TM), ALLEVYN(TM), IODOSORB(TM), SECURA(TM) and BIOSTEP(TM) advanced dressings.

At booth #401, Smith & Nephew will present its RENASYS EZ(TM) and RENASYS GO(TM) NPWT products as well as its VERSAJET(TM) hydrosurgery system and the full portfolio of advanced wound dressings.

"We look forward to viewing the impressive new clinical results achieved with Smith & Nephew NPWT advanced wound management products," said Robin Carlstein, Senior Vice President of Advanced Wound Devices at Smith & Nephew. "Smith & Nephew is committed to helping clinicians at every stage of wound treatment deliver the best possible care, and deliver value to their healthcare institutions. We are particularly pleased to see so many posters regarding our NPWT offerings, as they significantly deepen the solid body of clinical evidence supporting their efficacy and ease-of-use. NPWT is a critical part of our comprehensive platform for the preparation, protection and progression towards healing of advanced wounds."

The body of new NPWT data on display at SAWC includes the following posters:

-- Negative Pressure Wound Therapy as a Dressing for Split-Thickness Skin Grafts: Our Experience -- Julie A. O'Brien, MD; Genevieve B. Broderick, MD; Janice F. Lalikos, MD; Ronald Ignotz, PhD; Heather Strom, BS; and Raymond M. Dunn, MD, University of Massachusetts.

-- An Evaluation of the Introduction of an Alternative Negative Pressure Wound Therapy -- Theresa A. Hurd, RN, MScN, MSN (Community Health Nursing) Med ACNP, Canadian Health System.

-- Negative Pressure, Positive Energy: Wound Closure Without Pain -- Use of Negative Pressure Wound Therapy Over Matrix Regeneration Grafts -- Estelle A. Zanotti, RN, MSN, APN-CNS, CWOCN, CRRN, and Dr. Robert Rosenbloom, MD, FACS, St. Alexius Medical Center, Hoffman Estates, Illinois.

-- Management of Four Patients with Complicated Entercutaneous Fistula using Pouching System in Conjunction with Negative Pressure Therapy in a Long Term Acute Care Facility (LTAC) -- Anne Blevins, BSN, RN, WCC, Clinical Coordinator, Advanced Wound Care Team, Drake Center, Health Alliance of Greater Cincinnati.

-- Negative Pressure Wound Therapy for Fistula Management - Marc Gottlieb, MD; Judy Madura, RD, RN, DWOCN; Wendy Murphy, RN, BSN; Brenda Leon, RN, BSN; Sue Kennel, RN, BSN, CWCN; Dana Altman, RN, Banner Good Samaritan Medical Center, Wound Care Program, Phoenix, Arizona.

The 22nd Annual SAWC/WHS Spring Meeting is the largest gathering of multidisciplinary wound care clinicians in the United States. It will be held from Sunday, April 26th to Wednesday, April 29th at the Gaylord Texan Resort near Dallas.

About Smith & Nephew

Smith & Nephew is a global medical technology business, specializing in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2008 were $3.8 billion.

Forward Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Source: Smith & Nephew Inc

• Additional
• References
• Citations